It is expected that HIF-PHD inhibitors will improve renal fibrosis by modulating kidney ILC2 function, and the HIF/ILC2 axis can serve as a new therapeutic target of renal fibrosis and other tissue fibroses. The gene discussed is PDC; the disease is renal fibrosis.